for more on Novo and Pharmaceutical spring and Guggenheim's biotech analyst Sheamus Fernandez. Sheamus, your take on the Novo results. Uh yeah, so I guess it's not too surprising to the overall market uh what happened here.This was a high-risisk reward clinical study for Nova Nordisk. Um it was well communicated by the company that way. But that being said, uh the company has had a lot of challenges this year, largely from competition from Eli Liy, but it also faces pretty challenging year in 2026 and poten ...

Core Insights - Novo Nordisk faces significant challenges in 2023, primarily due to competition from Eli Lilly and setbacks in its clinical studies [2][3] - The company is attempting to expand its GLP-1 drug offerings into new markets, such as obesity treatment, but has encountered difficulties [3] - Eli Lilly's stock is performing exceptionally well, with a valuation reaching one trillion dollars, indicating strong market confidence in its products [4][6] Company Performance - Novo Nordisk has experienced a tough year, marked by pipeline issues and a failed clinical study [3] - The company plans to launch a new pill next year utilizing peptide technology, which may help regain market traction [5] - Eli Lilly is currently in a stronger position with leading products like Mounjaro and Zepbound, which are expected to drive future growth [6] Market Comparison - There is a competitive landscape between Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, with both drugs serving similar purposes but having different consumer perceptions [7][8] - Physicians report that patients tend to perform better on Mounjaro compared to Wegovy, suggesting a potential preference in the market [8] - Eli Lilly's upcoming drug, orphaglyphron, is anticipated to have significant market potential, with peak sales estimates between 30 to 50 billion [6]